Dr. Sherry Wu heads the cancer therapeutics lab.

Research Biography

Dr. Sherry Wu obtained her undergraduate training in Pharmacy at the University of Queensland. She subsequently received her Ph.D. degree in the field of cancer medicine at the University of Queensland in 2010. She then undertook postdoctoral translational cancer research fellowships at Johns Hopkins University and the University of Texas M.D. Anderson Cancer Center. In late 2017, Dr. Wu took up an academic position at UQ School of Biomedical Sciences to continue with her research in cancer therapeutics.

Dr. Wu has expertise in target discovery using large-scale experimental databases, in vitro and in vivo validation models, nanotechnology, and molecular biology techniques for studying mechanisms of action and resistance. Her research focuses on:

1) Developing strategies to overcome immune suppression in ovarian and breast cancers

 2) Developing novel nanoparticle platforms for tumor-targeted delivery

 3) Developing novel strategies to enhance patient survival in ovarian and breast cancers.

Qualifications
  • Graduate Certificate in Translational Cancer Research, the University of Texas M.D. Anderson Cancer Center (TRIUMPH program)
  • Doctor of Philosophy, The University of Queensland
  • Bachelor of Pharmacy, The University of Queensland
PhD and Mphil Supervision

For all enquiries regarding research supervision, please contact ask@uq.edu.au. For all enquiries regarding potential research projects, please contact Dr. Wu (sherry.wu@uq.edu.au).

Opportunities for New Researchers

Positions are available across our research program for undergraduates, honours students, PhD students, and postdoctoral fellows. If you are interested in joining our lab, please contact Dr. Wu (sherry.wu@uq.edu.au).

Potential research projects include, but not limited to:

Theme 1: Understand factors contributing to immune suppression in cancer

  • Investigate the mechanisms by which microRNA enhances anti-tumour immunity in ovarian cancer
  • Overcoming endothelial barriers for T-cell trafficking in ovarian and triple negative breast cancers

Theme 2: Develop clinically translatable nanosystems to break down immune barriers

  • Developing exosomal nanoparticle system to directly engineer T-cells in vivo
  • Using exosomal nanoparticles to generate an effective anti-tumour immune response
Selected Publications
Original Research Articles

Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, et al. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Molecular Cancer Therapeutics 2017, 16(5):966-976.

Wu, S.Y., Rupaimoole, R., Shen, F., Pradeep, S., Pecot, C.V., Ivan, C., et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications 2016, 7:111169.

Hatakeyama, H., Wu, S.Y., Lyons, Y.A., Pradeep, S., Wang, W., Huang, Q., et al. Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Reports 2016, 17(6):1621-31.

Miyake TM, Pradeep S, Wu SY, Rupaimoole R, Zand B, Wen Y, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research 2015, 21(14):3286-97.

Wu, S.Y., Yang, X.B., Gharpure, K., Hatakeyama, H., Egli, M., McGuire, M., et al. 2’-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications 2014, 5, 3459.

Rupaimoole, R.; Wu, S.Y.; Pradeep, S.; Ivan, C.; Pecot, C.V.; Gharpure, K.M.; et al. Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. Nature Communications 2014, 5:5202.

Pradeep, S., Kim, S.W., Wu, S.Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014, 26(1):77-91.

Pecot, C.V., Wu, S.Y., Bellister, S., Bhattacharya, R., Maharaj, A., Rodriguez-Aguayo, C., et al. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Molecular Cancer Therapeutics 2014, 13(12):2876-85.

Cho, M.S., Vasquez, H.G., Rupaimoole, R., Pradeep, S., Wu, S., Zand, B., et al. Cell Reports 2014, pii: S2211-1247(14)00114-4.

McCaskill, J.; Singhania, R., Burgess, M., Allavena, R., Wu, S.Y., Blumenthal, A., et al. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Molecular Therapy – Nucleic Acids 2013, 2:e96.

Wu, S.Y.; Chang, H.I.; Burgess, M.; McMillan N.A.J. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. Journal of Controlled Release 2011, 155(3):418-26.

Wu, S.Y., Singhania, A., Burgess, M., Putral, L., Kirkpatrick, C., Davies, N.M., et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models.  Gene Therapy 2011, 18(1): 14-22.

Singhania, A.*, Wu, S.Y.*, McMillan, N.A.J. Effective delivery of PEGylated siRNA-containing lipoplexes to extraperitoneal tumours following intraperitoneal administration. Journal of Drug Delivery 2011, e192562.

*These authors contributed equally to the work.

Khairuddin, N., Gantier, M.P., Blake, S., Wu, S.Y., Behlke, M.A., Williams, B.R.G., et al. SiRNA-induced immunostimulation through TLR7 promotes anti-tumoral activity against HPV-driven tumors in vivo. Immunology & Cell Biology 2011, 90(2):187-96.

Wu, S.Y.; Putral, L.N.; Liang M.; Chang H.I.; Davies N.M.; McMillan N.A.J. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharmaceutical Research 2009, 26(3):512-22.

Wu, S.; Campbell, C.; Koda, Y.; Blanchfield, J.T.; Toth, I. Investigation of the route of absorption of lipid and sugar modified Leu-enkephalin analogues and their enzymatic stability using the Caco-2 cell monolayer system. Medicinal Chemistry 2006, 2(2):203-11.

Review Articles

Lyons, Y., Wu, S.Y., Overwijk, W.W., Baggerly, K.A., Sood, A.K. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precision Oncology. (In Press)

Sercombe L., Veerati, T., Mohemani, F., Wu, S.Y., Sood, A.K., Hua, S. Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology 2015, 6:286.

Gharpure, K., Wu, S.Y., Li, C., Lopez-Berestein, G., and Sood, A.K. Nanotechnology: Future of oncotherapy. Clinical Cancer Research 2015, 21(14):3121-30.

Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; Sood, A.K. RNAi therapeutics: Drugging the undruggable. Science Translational Medicine 2014, 6:240ps7.

Hua, S.; Wu, S.Y. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Neuropharmacology 2013, 4: 143.

Wu, S.Y. and McMillan N.A.J. Lipidic systems for in vivo siRNA delivery. American Association of Pharmaceutical Scientists Journal 2009, 11(4):639-52.

Editorials/Commentary/Book Chapters

Hatakeyama, H., Wu, S.Y., Mangala, L.S., Lopez-Berestein, G., Sood, A.K. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2016,1402:189-97.

McCaskill, J.L., Wu, S., Khairuddin, N., and McMillan, N.A. Lowering the siRNA delivery barrier: Alginate Scaffolds and Immune stimulation. In: Peer D, editor. Nanotechnology for delivery of Therapeutic Nucleic Acids. Pan Stanford Publishing Pte. Ltd. pp. 193-216 (2013).

Wu, S.Y. and Sood A.K. New Roles Opined for OPCML. Cancer Discovery 2012, 2(2): 115–6.

Wu, S.Y. Cancer therapy hits its target. Australasian Science, 2010 April, p28-30.

Grants

2018-2020    Cancer Institute NSW Career Development Fellowship - Targeting the “undruggable”: Re-activating anti-tumour   immunity by silencing N-MYC in ovarian cancer and neuroblastoma (Declined, due to relocation to Brisbane)

2017-2018    National Institute of Health (NIH) R35 Maximizing Investigators’ Research Award - In vivo genetic engineering of T-cells for treatment of human diseases.

2017-2018    Australian Ovarian Cancer Research Foundation - Re-activating anti-tumour immunity by targeting N-MYC-Let7 axis in ovarian cancer.

2017-2024    National Institute of Health (NIH) R35 - Harnessing the power of exosomes for non-coding RNA delivery.

2016-2019    Ovarian Cancer Research Fund Alliance The Liz Tilberis Early Career Award - Re-activating anti-tumor immunity using non-coding RNAs.

2016-2017    Colleen’s Dream Foundation Pilot Study Grant - Using exosomes for detection of ovarian cancer.

2015             Texas Center for Cancer Nanomedicine Pilot study grant - Development of biomimetic nanosystems for delivering miRNAs for cancer treatment.

2014-2017    Foundation for Women’s Cancer - Caring Together, NY Ovarian Cancer Research Grant

2013-2015    Cancer Prevention Research Institute of Texas Keck Computational Cancer Biology Postdoctoral Fellowship

2013-2014    Texas Center for Cancer Nanomedicine Postdoc Research Award - A biomimetic bi-functional controlled release delivery platform for cancer treatment

2011-2014    Cancer Prevention Research Institute of Texas TRIUMPH (Translational Research in Multi-Disciplinary Program) Postdoctoral Fellowship

2011-2013    Ovarian Cancer Research Fund Ann Schreiber Mentored Investigator Grant - Novel anti-angiogenic strategies for ovarian cancer treatment.

2006-2009    NHMRC Postgraduate Scholarship - Delivery of siRNA for cancer treatment.